Asian Journal Of Social Pharmacy

Objective To systematically evaluate the quality of pharmacoeconomics on hypertension management, and provide reference for promoting the development of pharmacoeconomics in China. Methods Some Chinese databases including CNKI, VIP, Wanfang, as well as international databases such as PubMed and Web of Science were searched to collect studies of economic evaluation on hypertension management in China. The quality of health economic studies (QHES) scale was used to assess the quality of the literature and to analyze the current situation and shortcomings of pharmacoeconomics in the field of hypertension in China. Results and Conclusion A total of 363 articles were included in this study. The quality assessment results showed that the average score of pharmacoeconomics on hypertension management was 42.54 points. The quality of literature published by medical institutions was significantly lower than that published by universities/research institutes (41.25 vs. 54.68, P < 0.05). Among the 363 articles, 3.31% (12 articles) were of high quality (75-100 points), 29.20% (106 articles) were of moderate quality (50-74 points), 66.12% (240 articles) were of low quality (25-49 points), and 1.38% (5 articles) were of extremely low quality (0-24 points). These papers have such problems as unclear research perspectives, single research methods, ambiguous data sources, inappropriate study duration for disease characteristics, and insufficient sensitivity analysis factors. Overall, the quality evaluation of pharmacoeconomics on hypertension management in China is generally low with poor standardization, which should be improved in the future.